TABLE 1.
Immune scores, stromal scores and clinical characteristics of patients with rectal cancer
| Characteristic | No. | Percent (%) | Stromal score range | Immune score range |
|---|---|---|---|---|
| Age | ||||
| >60 | 52 | 62.65 | ‐1979.57 to 1522.96 | ‐627.18 to 2102.23 |
| ≤60 | 31 | 37.35 | ‐1647.38 to 437.50 | ‐656.67 to 1634.65 |
| Gender | ||||
| Male | 47 | 56.63 | ‐1831.95 to 736.53 | ‐656.67 to 1634.65 |
| Female | 36 | 43.37 | ‐1979.57 to 1522.96 | ‐627.18 to 2102.23 |
| TNM Stage | ||||
| I | 17 | 20.48 | ‐1500.59 to 710.82 | ‐656.67 to 1333.14 |
| II | 25 | 30.12 | ‐1440.11 to 353.92 | ‐477.23 to 1215.29 |
| III | 23 | 27.71 | ‐1979.57 to 1522.96 | ‐627.18 to 2102.23 |
| IV | 13 | 15.66 | ‐1831.95 to 736.53 | ‐650.76 to 1365.69 |
| Unknown | 4 | 4.82 | ‐1750.89 to −256.74 | ‐239.09 to 169.38 |
| T stage | ||||
| T1 | 4 | 4.82 | ‐1500.59 to −727.389 | ‐262.74 to 1308.84 |
| T2 | 17 | 20.48 | ‐1979.57 to 710.82 | ‐656.67 to 1333.14 |
| T3 | 56 | 67.47 | ‐1831.95 to 1522.96 | ‐650.76 to 2102.23 |
| T4 | 5 | 6.02 | ‐1167.63 to −242.44 | ‐627.18 to 1215.29 |
| N stage | ||||
| N0 | 44 | 53.01 | ‐1750.89 to 710.82 | ‐656.67 to 1333.14 |
| N1 | 25 | 30.12 | ‐1979.57 to 736.52 | ‐627.18 to 1634.65 |
| N2 | 12 | 14.46 | ‐1415.65 to 1522.96 | ‐650.76 to 2102.23 |
| Nx | 1 | 1.20 | ‐256.74 to −256.74 | 121. 05 to 121.42 |
| M stage | ||||
| M0 | 63 | 75.90 | ‐1879.57 to 1622.96 | ‐556.67 to 2202.23 |
| M1 | 13 | 15.66 | ‐1931.95 to 636.53 | ‐750.76 to 1265.69 |
| Mx | 5 | 6.02 | ‐1750.89 to 119.47 | 77.57 to 1215.29 |
| Unknown | 1 | 1.20 | ‐53.40 to −53.40 | 1196.84 to 1196.84 |
| Survival status | ||||
| Death | 72 | 86.75 | ‐1750.89 to 1522.96 | ‐656.67 to 2102.23 |
| Alive | 10 | 12.05 | ‐1979.57 to 24.80 | ‐627.18 to 557.27 |
| CEA | ||||
| ≤5 | 32 | 38.55 | ‐1647.38 to 1522.96 | ‐267.87 to 2102.23 |
| >5 | 19 | 22.89 | ‐1750.89 to 736.53 | ‐477.23 to 1634.65 |
| Unknown | 31 | 37.35 | ‐1979.57 to 450.95 | ‐656.67 to 1308.84 |
| Race | ||||
| White | 37 | 44.58 | ‐1979.57 to 1522.96 | ‐627.18 to 2102.23 |
| Black | 1 | 1.20 | ‐388.15 to −388.15 | 49.44 to 49.44 |
| Unknown | 44 | 53.01 | ‐1647.38 to 736.53 | ‐656.67 to 1396.93 |
| Venous invasion | ||||
| YES | 20 | 24.10 | ‐1562.90 to 1522.96 | ‐477.23 to 2102.23 |
| No | 46 | 55.42 | ‐1750.89 to 450.95 | ‐650.76 to 1634.65 |
| Unknown | 16 | 19.28 | ‐1979.57 to 736.53 | ‐656.67 to 1365.69 |
| Lymphatic invasion | ||||
| Yes | 32 | 38.55 | ‐1697.38 to 1472.96 | ‐700.76 to 2052.23 |
| No | 37 | 44.58 | ‐1700.89 to 760.82 | ‐577.18 to 1588.38 |
| Unknown | 13 | 15.66 | ‐1979.57 to 736.53 | ‐656.67 to 1365.69 |
| Perineural Invasion | ||||
| Yes | 8 | 9.64 | ‐1750.89 to 710.82 | ‐232.18 to 1634.65 |
| No | 19 | 22.89 | ‐1440.11 to 450.95 | ‐627.18 to 1538.38 |
| Unknown | 55 | 66.27 | ‐1979.57 to 1522.96 | ‐656.67 to 2102.23 |